Kerala Ayurveda has scheduled a board meeting on Friday, September 4, 2026, to consider a preferential issue of equity shares and convene its 34th Annual General Meeting.

Board agenda: two key items

The board meeting will take up two matters. First, it will consider and evaluate a proposal for a preferential issue of equity shares in one or more tranches, in accordance with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, subject to statutory and regulatory approvals as may be required. Second, the board will consider convening the 34th Annual General Meeting of the company.

34th AGM set for September 28, 2026

The 34th AGM is proposed to be held on Monday, September 28, 2026 at 11:00 am through Video Conferencing or Other Audio-Visual Means. The company noted that further details pertaining to the AGM will be informed in due course.

Trading window closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Regulating, Monitoring, Preventing and Reporting of Trading in Securities, the trading window for dealing in the company's securities has been closed for designated persons and their immediate relatives. The window will reopen 48 hours after the announcement of the outcome of the board meeting on the preferential issue of equity shares.

Key meeting details at a glance

The following table summarises the scheduled corporate actions:

The intimation was made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kerala Ayurveda Limited reported a consolidated net loss of ₹8.08 crore for the quarter ended June 30, 2026 (Q1FY26), widening significantly from a net loss of ₹2.03 crore in the corresponding period of FY25. Standalone results showed a net loss of ₹7.67 crore compared to a profit of ₹2.07 crore in Q1FY25, driven by rising operational costs and increased finance expenses. The Board of Directors approved these unaudited financial results on August 12, 2026, alongside the amalgamation of its wellness subsidiary and an employee stock option grant.

The company’s standalone revenue from operations fell to ₹22.53 crore in Q1FY26, down from ₹24.57 crore in Q4FY26 but up from ₹17.57 crore in Q1FY25. Total expenses rose to ₹31.84 crore from ₹24.99 crore year-on-year, primarily due to a surge in employee benefits expense to ₹13.18 crore and finance costs increasing to ₹2.81 crore. Consolidated revenue from operations stood at ₹33.19 crore, slightly lower than the ₹34.74 crore reported in the preceding quarter but up from ₹28.61 crore in Q1FY25.

Beyond financial results, the Board approved the Scheme of Amalgamation between Kerala Ayurveda Limited and its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre Private Limited. The merger, subject to shareholder and National Company Law Tribunal approval, aims to streamline operations, reduce regulatory compliances, and integrate assets including intellectual property. The transaction does not fall under related-party transaction regulations as it involves a holding company and its wholly-owned subsidiary.

The Nomination and Remuneration Committee granted 64,875 Employee Stock Options under the Kerala Ayurveda Employee Restricted Stock Unit Plan, 2023. The options carry an exercise price of ₹10 per share and vest according to the scheme’s terms, exercisable within one year post-vesting. Additionally, the Board recommended the re-appointment of Non-Executive Director Ramesh Vangal at the ensuing Annual General Meeting on September 28, 2026.

What the Numbers Show

The divergence between standalone profitability trends highlights structural cost pressures within the parent entity. While consolidated revenues grew 16% year-on-year, the standalone segment swung from a profit to a significant loss, indicating that overheads and finance costs are outpacing top-line growth in the core Indian operations. The acquisition of the remaining 26% stake in Ayurvedagram during the period, executed via a share swap of 304,887 equity shares, has fully consolidated this subsidiary, potentially impacting future comparability as its wellness center revenues and margins blend directly into the group’s primary healthcare and pharmaceutical focus.